In contrast, in other WT cell lines, including MM, mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL) cell lines, TriBAFF/CD3/ABDCon exhibited inferior cytotoxicity compared with blinatumomab (Fig. S12A), which was potentially due to the significantly lower expression levels of BAFF-R, BCMA, and TACI in these cells relative to those of CD19. This evidence concerns the gene CD19 and Miyoshi myopathy.